Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients

In chronic myeloid leukemia (CML) and Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) patients who fail imatinib treatment, BCR-ABL1 mutation profiling by Sanger sequencing (SS) is recommended before changing therapy since detection of specific mutations influences second-generation t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncotarget 2016-04, Vol.7 (16), p.21982-21990
Hauptverfasser:	Soverini, Simona, De Benedittis, Caterina, Polakova, Katerina Machova, Linhartova, Jana, Castagnetti, Fausto, Gugliotta, Gabriele, Papayannidis, Cristina, Mancini, Manuela, Klamova, Hana, Salvucci, Marzia, Crugnola, Monica, Iurlo, Alessandra, Albano, Francesco, Russo, Domenico, Rosti, Gianantonio, Cavo, Michele, Baccarani, Michele, Martinelli, Giovanni
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Dasatinib - therapeutic use DNA Mutational Analysis - methods Drug Resistance, Neoplasm - genetics Female Fusion Proteins, bcr-abl - genetics High-Throughput Nucleotide Sequencing - methods Humans Imatinib Mesylate - therapeutic use Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Male Middle Aged Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics Protein Kinase Inhibitors - therapeutic use Research Paper Retrospective Studies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!